Clinical Evaluation and Post-marketing Surveillance of Medical Devices in the USA

Abstract
The medical device industry makes a colossal number of items, ranging from invasive gloves to non-natural joints to imaging gear, and assumes a pivotal job in growing new therapeutic advancements that can improve the capacity to analyse and treat disease. Like physician-endorsed drugs, medical devices are controlled by the Food and Drug Administration (FDA). In any case, the administrative system that the Congress has built up for medicinal gadgets is less stringent in numerous regards, due to a limited extent to fundamental contrasts between therapeutic gadgets and physician-endorsed drugs.

Most adequate gadgets can be advertised without earlier FDA audit, and most medium-chance gadgets are required to exhibit that they are "considerably equal" to a current gadget before being promoted. Not many gadgets need to show that they are protected and powerful before being showcased. Post-market surveillance is done to an abnormal degree, since the FDA and other skilled specialists will get reports from all items in their nations and reports from different nations. The FDA's surveillance of devices after they become available to the public has also been limited, although improvements are being made through initiatives such as requiring unique device identifiers on all devices.

The point of this article is to cover the clinical assessment and its requisites alongside the post-showcase reconnaissance of medicinal devices.

Key words: Medical devices, FDA, post-market surveillance

Introduction

The US medical device makers' market size was estimated at USD 154.0 billion in 2017 and is foreseen to display a CAGR of 5.0% over the timeframe of Figure 1. The increasing prevalence of constant sicknesses and the expanding geriatric population in the nation are among the chief market drivers.



Figure 1: US medical device manufacturers market size comparison

As indicated by the US Statistics Bureau, 49 million or 15.0% of the population were classified as geriatric in 2015. The agency predicts that, by 2023, the geriatric population will represent 23.0% of the US population. The beginning of constant ailments is more regularly pervasive between the ages of 45 and 54.

Consequently, the increment in the geriatric populace is what is principally driving interest for medical device arrangements all around.[1]

The United States remains the greatest therapeutic gadget showcase on the planet, with a market size of around $156 billion, and it was responsible for around 40 per cent of the overall number of restorative gadgets publicised in 2017. US payments for restorative gadgets in orders seen by the Department of Commerce (DOC) were more than $41 billion in that year. Generally, the inspiration driving a medicinal gadget isn't cultivated by pharmacological, immunological, or metabolic techniques.

The industry is directly responsible for around 2 million jobs in the United States. Restorative advancement clearly accounts for more than 500,000 of these vocations. More than 80 per cent of therapeutic gadget associations in the United States involve under 50 agents and many new organisations have for all intents and purposes zero payment arrangements. Since progress means the therapeutic gadget sector achieves crucial better ways to deal with, treat and examine infirmities, the restorative gadget division should continue creating at a positive rate later on.[2]

Classification of Medical Devices[3]

The Food and Drug Administration (FDA) has established classifications for approximately 1700 different generic types of devices and grouped them into 16 medical specialities, referred to as panels. The three classes and the requirements which apply to them are:

Device Class and Regulatory Controls

1. Class I General Controls
   - With Exemptions
   - Without Exemptions

2. Class II General Controls and Special Controls
   - With Exemptions
   - Without Exemptions

3. Class III requires 510(k) and Pre-market Approval
   Types of applications
   - Investigational device exemption (IDE) for clinical studies
   - Pre-market notification 510(k)
   - Pre-market approval (PMA)
   - Humanitarian device exemptions (HDE) if applicable

Clinical Evaluation of Medical Devices

Clinical investigation of medical devices are of two types:

- Pilot clinical investigation
- Pivotal clinical investigation.

Product – Category	Medical device
Market filing	USA
Regulating agency	USFDA/CDRH
Regulating ministry	Department of Health and Human Services
Regulations	21 CFR 800-1299
	Clinical Evaluation
Types of clinical investigation	Pilot & Pivotal Investigation
Types of device study	**Device Study** 
Application form **Elements required**	Investigational Device Exemption (significant risk devices) • Name and address of support • A report of earlier examinations must incorporate reports of all earlier clinical, creature study, and research facility testing of the gadget • Investigational plan
Mode of submission	Electronic submission gateway
Timeline for approval	Within 30 days
Submission, review & approval process	Submission of a complete IDE application FDA notifies the sponsor via email receipt of an IDE application **FDA** **FDA** Approve, approve with modification Disapproved Additional Information required **30 days** Clinical investigation may begin if IRB approval is obtained
Reporting of adverse events	**IDE reports-** Sponsor reports Investigator reports **Sponsor reports**

What should be reported	Whom to be reported	No. of days
Progress reports (or annual reports)	All reviewing IRBs, FDA (for a significant risk device)	At least yearly
Final report	FDA and all reviewing IRBs (for a significant risk device) All reviewing IRBs (for a non-significant risk device)	Within 30 working days. Within six months after the completion or termination of the investigation. Within six months after completion or termination.

Investigator reports

What should be reported	Whom to be reported	No. of days
Progress reports	Sponsor, the monitor, and the reviewing IRB	Regular intervals but no less than on a yearly basis.
Final report	Sponsor and the reviewing IRB	Within three months after completion or termination.

Clinical Evaluation Requirements

- **Investigational Device Exemption (IDE)**[4]
  An investigational gadget exclusion permits the investigational gadget to be utilised in a clinical report so as to gather wellbeing and adequacy information. An IDE need not be submitted before the investigation is started.

- **Significant Risk Devices**
  A huge hazard gadget exhibits a potential for genuine hazard to wellbeing, security or welfare of a subject. These gadgets require both FDA and an institutional survey board (IRB) endorsement before the instigation of a clinical report.
  E.g.: Sutures, cardiac pacemakers, hydrocephalus shunts and orthopaedic inserts.

- **Non-significant Risk Devices**
  A non-noteworthy hazard gadget doesn't represent a huge hazard to human subjects. These gadgets require just IRB endorsement before the commencement of a clinical report. Patrons of these gadgets are not required to present an IDE application to the FDA for endorsement.
  E.g.: Daily-wear contact focal points and focal point arrangements, ultrasonic dental scalers and Foley catheters.

Factsheet of USA
Post-marketing Surveillance
(Electronic Medical Device Reporting)

Class of devices	Class II & Class III
Adverse event reporting form	Form 3500A
Timeline of reporting	Three years (basic)
Mode of submission	Electronic submission (ESG)
Software used	e-Submitter, HL-7

Table 1: Factsheet for Post-marketing Surveillance



Flowchart 1: Process of e-MDR

Conclusion

All the most at risk devices are exposed to clinical testing as they have the most extreme hazards. Be that as it may, once in a while even the most thorough clinical testing of trial gadgets will leave some security and adequacy addresses unanswered. Simultaneously, more extensive circulation of new innovation and longer clinical experience may reveal startling concerns. They should likewise answer to the US Food and Drug Administration (FDA), giving patient statistical information, clinical data, and strategy subtleties. This shows the FDA's guideline of medical devices proceeds after they enter the market and that the guidelines for post-market surveillance are exceptionally stringent in the USA.

REFERENCES

1. Introduction of medical devices and market overview of medical devices in USA, available at https://www.grandviewresearch.com/industry-analysis/us-medical-device-manufacturers-market [citation 13 May 2019]
2. Market overview of medical devices in USA, available at https://www.selectusa.gov/medical-technology-industry-united-states [citation 13 May 2019]
3. Classification of medical devices in USA, available at https://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm2005371.htm [citation 13 May 2019]
4. Clinical evaluation requirements, Investigational device exemptions, available at https://www.fda.gov/medical [citation 13 May 2019]
5. Electronic submission gateway (ESG), available at https://www.fda.gov/industry/electronic-submission [citation 13 May 2019]

Balamuralidhara V.

Balamuralidhara V. is an assistant professor at the Department of Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysore – 570 015, Karnataka, India.

Email: baligowda@gmail.com

Kavya S. Reddy

Kavya S Reddy is a student in the Regulatory Affairs Group in the Department of Pharmaceutics at the JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysore – 570 015, Karnataka, India.

Email: kavyasreddy8315@gmail.com

Sanhita Singha Roy



Sanhita Singha Roy is a research scholar in the Regulatory Affairs Group in the Department of Pharmaceutics at the JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysore – 570 015, Karnataka, India.

Email: sanhitaroy1993@gmail.com

M P Venkatesh

M P Venkatesh is an assistant professor in the Department of Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysore – 570 015, Karnataka, India.

Email: venkateshmpv@jssuni.edu.in